Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (7714)	1/12/2003 7:51:21 PM
From: Mike	Read Replies (2) \| Respond to of 52153

First I want to apologize to those who have seen this message a couple times. I am looking for help in trying to determine price valuation for a biotech that I have been following. I have sent this message to a few people and posted it on a few boards. So I am not a pumper and dumper. Just looking for insight into this company. Looking to get some discussion going on this biotech that has great promise. The best thing is that it has an FDA approved product that may double in sales in '03. The company is MDCO-The Medicine Company. The product they have is called Angiomax. First, I would like to try to revive the MDCO board here. MDCO has delivered and has hit a homerun in 2002. It completed and presented results on the Angiomax product just last month. All primary and secondary endpoints of the trial were met. Sales for '02 ended with a high note. Earnings for Q4 '02 will released in early Feb. Sales for '02 will be in the $38M range. From the sources that I have in the field it has been estimated that November '02 were a record of approx $4M. The sales for Dec '02 were in the range of $5M. Projections have been made for '03 during the conference listed below. mapdigital.com. During this conference the company stated that sales for '03 would be in the $70-$90M range. This could be over a 100% increase!!! I think that this company is a "diamond in the rough". It is followed by very few analyst and needs more exposure. I think longs will be rewarded handsomely if the company executes. Take a look and let us know what you think. Thanks in advance, Mike